BAGNEUX, France, Sept. 3, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that multiple members of its management team will present and host investor meetings at the following events in September:
- Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will present at the Rodman & Renshaw 17th Annual Global Investment Conference in New York, NY, on Wednesday, September 9, 2015 at 11:40 am ET.
- Charles Ruban, Chief Development Officer, will present at the 6th Annual Credit Suisse Small/Mid Cap Conference in New York, NY, on Thursday, September 17, 2015 at 1:50 pm ET.
- Charles Ruban, Chief Development Officer, will present at the 2015 Morgan Stanley Global Healthcare Conference in New York, NY, on Friday, September 18, 2015 at 2:45 pm ET.
- David Schilansky, Chief Operating Officer, will host investor meetings during the 2nd Annual Goldman Sachs Biotech and Emerging Pharma Symposium in London, UK on Friday, September 10, 2015, the 6th annual Leerink Partners Healthcare Summit at the Meadowood Resort in Napa Valley, September 16-18, 2015, and the Annual Credit Suisse Investor Bus Trip in Paris, France, on Wednesday, September 23, 2015.
Live audio webcasts of the Credit Suisse Small/Mid Cap Conference and Morgan Stanley's conference will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentations will also be available on DBV's website within 48 hours after the events.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
|DBV Technologies Contacts|
| Nathalie Donne |
Director, Corporate Communication & Business Development
Tél. : +33(0)1 55 42 78 72
| Susanna Mesa |
VP Finance, US Investor Relations & Strategy
Tél. : +1 917-346-3447
|DBV Technologies Media Contacts US & Europe|
| Marion Janic |
Rooney & Associates
Tél. : +1-212-223-4017
| Caroline Carmagnol |
Alize RP - Relation Presse
Tél. : +33(0)6 64 18 99 59
DBV Technologies to Attend Upcoming Investor Conferences and Events http://hugin.info/156437/R/1949385/708378.pdf